Thierry BOIRON

About Thierry BOIRON

Thierry Boiron is a key figure in the governance of Laboratoires Boiron, the French pharmaceutical group best known for homeopathic medicines and for its international footprint. As a member of the founding family, he represents continuity within a long-standing family-owned listed company that has built its identity over several generations. Boiron’s corporate governance disclosures show that he has recently held senior leadership responsibilities, including Deputy General Manager and Board member, with a strong role in the company’s strategic direction. In March 2024, the group announced a governance change in which Thierry Boiron was appointed Chief Executive Officer, while Anabelle Flory-Boiron became Chair of the Board. That move underscored his operational importance at the center of the group’s leadership. More recently, a November 2025 filing stated that he decided to end his mandate as Deputy General Manager effective December 31, 2025, while remaining involved as President of Boiron Développement and continuing as a BOIRON SA director. His career is closely tied to the evolution of the family business and to the challenges of managing a listed healthcare company: corporate governance, family succession, regulatory discipline, industrial performance, and international development. Boiron’s own communications also emphasize Thierry Boiron’s attachment to an integrative vision of healthcare and to a more human, sustainable approach to medicine. In a sector shaped by regulatory scrutiny and public debate, he stands out as a leader who combines family legacy, strategic oversight, and corporate adaptation, helping steer the group through both continuity and change.